

ARTICLE

Received 18 Apr 2016 | Accepted 30 Sep 2016 | Published 9 Nov 2016

DOI: 10.1038/ncomms13416

OPEN

# Functional competence of a partially engaged GPCR- $\beta$ -arrestin complex

Punita Kumari<sup>1</sup>, Ashish Srivastava<sup>1</sup>, Ramanuj Banerjee<sup>1</sup>, Eshan Ghosh<sup>1</sup>, Pragma Gupta<sup>1</sup>, Ravi Ranjan<sup>1</sup>, Xin Chen<sup>2</sup>, Bhagyashri Gupta<sup>1</sup>, Charu Gupta<sup>1</sup>, Deepika Jaiman<sup>1</sup> & Arun K. Shukla<sup>1</sup>

G Protein-coupled receptors (GPCRs) constitute the largest family of cell surface receptors and drug targets. GPCR signalling and desensitization is critically regulated by  $\beta$ -arrestins ( $\beta$ arr). GPCR- $\beta$ arr interaction is biphasic where the phosphorylated carboxyl terminus of GPCRs docks to the N-domain of  $\beta$ arr first and then seven transmembrane core of the receptor engages with  $\beta$ arr. It is currently unknown whether fully engaged GPCR- $\beta$ arr complex is essential for functional outcomes or partially engaged complex can also be functionally competent. Here we assemble partially and fully engaged complexes of a chimeric  $\beta_2V_2R$  with  $\beta$ arr1, and discover that the core interaction is dispensable for receptor endocytosis, ERK MAP kinase binding and activation. Furthermore, we observe that carvedilol, a  $\beta$ arr biased ligand, does not promote detectable engagement between  $\beta$ arr1 and the receptor core. These findings uncover a previously unknown aspect of GPCR- $\beta$ arr interaction and provide novel insights into GPCR signalling and regulatory paradigms.

<sup>1</sup>Department of Biological Sciences and Bioengineering, Indian Institute of Technology, Kanpur 208016, India. <sup>2</sup>School of Pharmaceutical Engineering and Life Sciences, Changzhou University, Changzhou, Jiangsu 213164, China. Correspondence and requests for materials should be addressed to A.K.S. (email: arshukla@iitk.ac.in).

**G** protein-coupled receptor (GPCR) family consists of ~800 different members that exhibit a highly conserved seven transmembrane architecture<sup>1</sup>. GPCRs bind to an incredibly diverse range of ligands, still, their signalling and regulatory mechanisms are primarily conserved<sup>2</sup>. GPCR signalling and downregulation is critically mediated by  $\beta$ arrs which on one hand, terminate G protein coupling presumably by steric hindrance and on the other, initiate G protein independent signalling cascades<sup>3</sup>. There has been a remarkable progress in structural visualization of GPCRs in the recent years<sup>4</sup>. However, structural details of GPCR- $\beta$ arr interaction have just started to emerge and still remain in infancy. Interaction of the N-domain of arrestins with phosphorylated carboxyl terminus of GPCRs is the first step in receptor-arrestin binding. Interestingly, a number of biophysical studies using spectroscopy approaches have suggested the engagement of different arrestin loops with the activated receptor core as the second step of interaction<sup>5-8</sup>. Crystal structure of rhodopsin with isolated finger loop peptide has directly established a binding interface between the receptor core and the finger loop of visual arrestin<sup>9</sup>. Recently determined crystal structure of rhodopsin-arrestin complex also exhibits an engagement of the receptor core with arrestin<sup>10</sup> although the carboxyl terminus of rhodopsin in this complex is covalently fused and not phosphorylated. Recent visualization of  $\beta_2V_2R$ - $\beta$ arr1 complex by negative stain electron microscopy and cross-linking has directly demonstrated a biphasic mechanism of GPCR- $\beta$ arr interaction<sup>11</sup>. In the first step, the phosphorylated carboxyl terminus of GPCRs interacts with the N-domain of  $\beta$ arrs and in the second step,  $\beta$ arrs engage with the cytoplasmic surface of the transmembrane bundle of the receptor (that is, receptor core) (Fig. 1a).

The functional repertoire of GPCR- $\beta$ arr signalling axis is quite broad and spans a wide range of cellular and physiological processes<sup>3,12-14</sup>. This is primarily mediated by a large number of interactions of  $\beta$ arrs and their abilities to scaffold a wide array of kinases and other signalling molecules<sup>12,13</sup>. However, the structural and mechanistic requirements for such a broad functional coverage of GPCR- $\beta$ arr interaction remains currently unexplored. In particular, whether a fully engaged GPCR- $\beta$ arr complex is essential for triggering downstream functional outcomes or even partially engaged complexes might display functional competence remains currently unknown. Phosphorylation of the carboxyl terminus of GPCRs is the primary determinant for  $\beta$ arr interaction and this first step of biphasic interaction represents the high-affinity component in GPCR- $\beta$ arr complex<sup>15-17</sup>. Direct visualization of a partially engaged  $\beta_2V_2R$ - $\beta$ arr1 complex<sup>11</sup> associated solely through the phosphorylated carboxyl terminus of the receptor by electron microscopy suggests that core interaction may be dispensable for stable assembly of the complex. However, functional capabilities of such a partially engaged receptor- $\beta$ arr complex remain currently unexplored.

Accordingly, here we set out to investigate whether a  $\beta_2V_2R$ - $\beta$ arr1 complex associated only through the phosphorylated carboxyl terminus of the receptor and lacking the core interaction might be functionally competent. We focus on recruitment and activation of ERK (extracellular signal-regulated kinase) MAP (mitogen-activated protein) kinase, a readout that has become quintessential for  $\beta$ arr mediated GPCR signalling, and receptor endocytosis. We assemble partially and fully engaged  $\beta_2V_2R$ - $\beta$ arr1 complexes, validate them by fluorescence spectroscopy and discover, in contrast with generally believed notion, that the core interaction in this complex is dispensable for ERK2 binding and activation. We also find that a receptor mutant lacking the core interaction with  $\beta$ arr efficiently undergoes agonist promoted internalization. Moreover, we also


discover that a  $\beta$ arr biased ligand does not promote core interaction between the receptor and  $\beta$ arr.

## Results

**Partially and fully engaged  $\beta_2V_2R$ - $\beta$ arr1 complexes.** Reconstitution of a stable and functional GPCR- $\beta$ arr complex for biophysical studies still remains very challenging. Recently, a strategy has been described for the isolation of a stable  $\beta$ arr1 complex with a chimeric  $\beta_2$  adrenergic receptor ( $\beta_2AR$ ) harbouring the carboxyl terminus of the arginine vasopressin subtype 2 receptor ( $V_2R$ ), referred to as  $\beta_2V_2R$  (ref. 11).  $\beta_2V_2R$  displays  $\beta_2AR$  pharmacology but tighter binding with  $\beta$ arr<sup>18</sup>. Stable  $\beta_2V_2R$ - $\beta$ arr1 complex can be isolated through coexpression of the receptor and  $\beta$ arr1 in cells followed by stabilization using a synthetic antibody fragment (referred to as Fab30) (ref. 11). In order to make this strategy more versatile and amenable to direct biophysical studies, we first assessed the feasibility of  $\beta_2V_2R$ - $\beta$ arr1-Fab30 complex assembly using purified components *in-vitro* (Fig. 1b). We immobilized purified Fab30 (Supplementary Fig. 1 and Supplementary Fig. 2A) on a polystyrene surface (MaxiSorp 96 well plate) as an anchor to stabilize the complex followed by addition of purified  $\beta$ arr1 and N-terminally FLAG-tagged  $\beta_2V_2R$  (Supplementary Fig. 2B and Supplementary Fig. 3). After rigorous washing of the surface, we visualized the assembly of the complex using HRP-coupled anti-FLAG M2 antibody. We observed a robust assembly of  $\beta_2V_2R$ - $\beta$ arr1 complex that is sensitive to agonist occupancy and phosphorylation status of the receptor, suggesting the formation of a cellularly and pharmacologically relevant complex (Fig. 1c and Supplementary Fig. 2C-E).

As mentioned earlier, in biphasic GPCR- $\beta$ arr interaction, the first step depends primarily on phosphorylation of carboxyl terminus of the receptor while the second step requires an activated receptor core (that is, transmembrane bundle). Therefore, in order to generate partially and fully engaged complexes, we designed an experimental scheme (Fig. 1d) where we trigger receptor phosphorylation in cells by stimulating them with a low-affinity full agonist, isoproterenol and then wash off the agonist in subsequent purification steps. This leads to purification of ligand free  $\beta_2V_2R$  with phosphorylated carboxyl terminus (referred to as  $^{Apo}\beta_2V_2R^{phos}$ ). Subsequent incubation with high-affinity partial inverse agonist (carazolol) or high-affinity full agonist (BI-167107) results in  $^{Inact}\beta_2V_2R^{phos}$  (inactive receptor core with phosphorylated carboxyl terminus) and  $^{act}\beta_2V_2R^{phos}$  (active receptor core with phosphorylated carboxyl terminus), respectively. These two species of the  $\beta_2V_2R$  provide us a handle to assemble partially (that is, tail only engaged) and fully (that is, tail + core engaged) associated  $\beta_2V_2R$ - $\beta$ arr1 complexes and evaluate their functional competence *in-vitro*. As presented in Fig. 1e,f, both, the  $^{Inact}\beta_2V_2R^{phos}$  and the  $^{act}\beta_2V_2R^{phos}$  exhibited robust complex formation with  $\beta$ arr1 and presumably represent, partially and fully engaged  $\beta_2V_2R$ - $\beta$ arr1 complexes, respectively.

In order to confirm the nature of these complexes with respect to tail and core engagement, we utilized a bimane fluorescence spectroscopy approach. Extensive previous studies have used bimane labelling in the finger loop of visual arrestin to study its interaction with rhodopsin and reported that rhodopsin-arrestin interaction leads to a significant decrease in bimane fluorescence<sup>5,9,19,20</sup>. Direct engagement of finger loop of visual arrestin with rhodopsin has also been documented by NMR<sup>21</sup> and crystallography<sup>9</sup>. Crystal structure of rhodopsin-arrestin complex also reveals an engagement of the finger loop of visual arrestin with the transmembrane core of rhodopsin<sup>10</sup>. More recently, chemical cross-linking and structural modelling of




**Figure 1 | Assembly of partially and fully engaged  $\beta_2V_2R$ - $\beta$ arr1-Fab30 complex.** (a) Schematic representation of biphasic GPCR- $\beta$ arr interaction.  $\beta$ arr interacts with activated and phosphorylated GPCRs in a biphasic fashion where the first step is binding of  $\beta$ arr through the phosphorylated carboxyl terminus and the second step is the engagement of  $\beta$ arr with the 7TM core of the receptor. The receptor component is shown in grey, phosphorylated carboxyl terminus in yellow and  $\beta$ arr 1 in blue/magenta. (b) Schematic representation of an ELISA-based approach for *in-vitro* assembly of  $\beta_2V_2R$ - $\beta$ arr1 complex. Purified Fab30 is immobilized on solid support as an anchor to capture the complex followed by incubation with purified  $\beta_2V_2R$  and  $\beta$ arr1. Formation of  $\beta_2V_2R$ - $\beta$ arr1 complex is visualized using HRP-coupled anti-FLAG M2 antibody through detection of FLAG tagged  $\beta_2V_2R$ . (c) Fab 30 assisted *in-vitro* assembly of  $\beta_2V_2R$ - $\beta$ arr1 complex. Agonist bound and phosphorylated  $\beta_2V_2R$  ( $Act\beta_2V_2R^{phos}$ ) forms a stable complex while inverse agonist bound and non-phosphorylated  $\beta_2V_2R$  ( $Inact\beta_2V_2R^{non-phos}$ ) does not exhibit any detectable complex formation. (d) An experimental set-up to assemble ‘tail only’ engaged and ‘fully’ engaged  $\beta_2V_2R$ - $\beta$ arr1 complex *in-vitro*.  $\beta_2V_2R$  is coexpressed with GRK2<sup>CAAX</sup> in cultured Sf9 cells and 66 h post-infection, cells are stimulated with a low-affinity agonist (Isoproterenol) to trigger receptor phosphorylation. Subsequently, the receptor is purified by affinity chromatography and the ligand is washed off during purification to yield ligand free phosphorylated  $\beta_2V_2R$  ( $Act\beta_2V_2R^{phos}$ ). Incubation with inverse agonist (carazolol) or high-affinity full agonist (BI-167107) yields  $Inact\beta_2V_2R^{phos}$  and  $Act\beta_2V_2R^{phos}$ , respectively. (e) Both, the  $Inact\beta_2V_2R^{phos}$  and  $Act\beta_2V_2R^{phos}$  form a stable complex with  $\beta$ arr1 as assessed by ELISA approach and potentially represent ‘tail only’ and ‘fully’ engaged complexes, respectively. (f) Formation of ‘tail only’ engaged and ‘fully’ engaged complexes as assessed by coimmunoprecipitation experiment. This experiment was repeated three times with identical results and a representative image is shown. Signals in c and e are normalized with  $Act\beta_2V_2R^{phos}$  +  $\beta$ arr1 + Fab30 condition as 100%. Data presented in c and e represent mean  $\pm$  s.e.m. of three independent experiments each carried out in duplicate and analysed using one-way ANOVA with Bonferroni post-test (\*\*\* $P$  < 0.001).

$\beta_2V_2R$ - $\beta arr1$  complex has also identified the finger loop of  $\beta arr1$  (residues 62-72) as a major interaction interface with the seven transmembrane core of the receptor<sup>11</sup> (Fig. 2a). Therefore, we first designed a cysteine-less  $\beta arr1$  mutant and then exchanged Leu<sup>68</sup> in the finger loop with a cysteine (referred to as  $\beta arr1^{L68C}$ ). We selected L<sup>68C</sup> based on previous studies with rhodopsin-visual arrestin system that have used the corresponding position (L<sup>72C</sup>) in the finger loop<sup>5,6,19,20,22</sup>. We subsequently purified  $\beta arr1^{L68C}$  and labelled it with an environmentally sensitive fluorophore monobromobimane (mBBr) at Cys<sup>68</sup>. Based on rhodopsin-arrestin studies, we reasoned that the environment of mBBr should change upon the engagement of the finger loop with the receptor core and, therefore, a change in mBBr fluorescence intensity will reflect the core interaction between  $\beta_2V_2R$  and  $\beta arr1$ . We confirmed the functionality of mBBr-labelled  $\beta arr1$  with respect to its binding with agonist occupied and phosphorylated  $\beta_2V_2R$  by coimmunoprecipitation assay (Fig. 2b). We then tested  $\beta_2V_2R$ - $\beta arr1$ -Fab30 complex by fluorescence spectroscopy and interestingly found that incubation of  $act\beta_2V_2R^{phos}$  with mBBr-labelled  $\beta arr1$  indeed resulted in a decrease in fluorescence intensity while that of  $inact\beta_2V_2R^{phos}$  does not (Fig. 2c,d). Considering that both  $inact\beta_2V_2R^{phos}$  and  $act\beta_2V_2R^{phos}$  interact with  $\beta arr1$  comparably, this observation suggest that the complexes of  $\beta arr1$  with  $inact\beta_2V_2R^{phos}$  and  $act\beta_2V_2R^{phos}$  in fact represent, partially engaged ('tail only') and fully engaged ('tail + core') complexes, respectively.


In order to further confirm this, we used an alternative approach where we first assembled a complex of  $Apo\beta_2V_2R^{phos}$  with  $\beta arr1$  and then incubated it with either an inverse agonist or agonist to generate partially and fully engaged complexes, respectively. We reasoned that  $Apo\beta_2V_2R^{phos}$  should form a complex with  $\beta arr1$  primarily driven through the phosphorylated tail but it might also engage some core interaction owing to the constitutive activity of the receptor (Fig. 3a). We anticipated that incubation of this complex with inverse agonist should destabilize (and presumably ablate) the core interaction while agonist should further stabilize the core interaction. As presented in Fig. 3b,c,  $Apo\beta_2V_2R^{phos}$  indeed forms a stable complex with  $\beta arr1$ , which is physically not altered by incubation with either the inverse agonist or agonist. Interestingly, however, bimane fluorescence level in  $Apo\beta_2V_2R^{phos}$ - $\beta arr1$ -Fab30 complex was lower compared with  $\beta arr1$  (+ Fab30), suggesting a basal level of core engagement in this complex (Fig. 3d,e). Incubation of this complex with agonist resulted in a robust decrease in fluorescence intensity suggesting the engagement of core interaction. On the other hand, incubation with inverse agonist led to an increase in bimane fluorescence bringing it up to  $\beta arr1$  alone level indicating disengagement of basal core interaction (Fig. 3d,e).

In order to further corroborate that bimane fluorescence quenching is a reliable read out of core interaction, we tested a panel of receptor ligands with different efficacies on preformed  $Apo\beta_2V_2R^{phos}$  complex. Again, incubation of pre-formed complex with these ligands does not alter the physical interaction as assessed



**Figure 2 | Validation of partially and fully engaged complexes by fluorescence spectroscopy.** (a) Structural model of  $\beta_2AR$ - $\beta arr1$  complex deduced based on negative-stain electron microscopy, cross-linking experiments and hydrogen-deuterium exchange mass-spectrometry reveals finger loop of  $\beta arr1$  as a key component of the core interaction. L<sup>68</sup> in the finger loop of  $\beta arr1$  was changed to cysteine in a cysteine-less  $\beta arr1$  and monobromobimane was attached to this cysteine by chemical coupling. Upon core interaction, bimane fluorescence intensity decreases either due to change in chemical environment or quenching by a tyrosine/tryptophan residue in the vicinity. (b) Functional validation of bimane labelled  $\beta arr1$  by its interaction with purified  $\beta_2V_2R$ . Similar to wild-type  $\beta arr1$ , bimane labelled  $\beta arr1$  also forms a complex with agonist occupied and phosphorylated  $\beta_2V_2R$ . The experiment was repeated twice with identical results and a representative image is shown. (c) Incubation of  $act\beta_2V_2R^{phos}$  but not  $inact\beta_2V_2R^{phos}$  with bimane labelled  $\beta arr1$  leads to a decrease in bimane fluorescence. Considering equivalent physical interaction of  $act\beta_2V_2R^{phos}$  and  $inact\beta_2V_2R^{phos}$  (as presented in Fig. 1e,f), bimane fluorescence data suggests that  $act\beta_2V_2R^{phos}$  engages the core interaction while the  $inact\beta_2V_2R^{phos}$  does not. These data suggest that  $inact\beta_2V_2R^{phos} + \beta arr1 + Fab30$  and  $act\beta_2V_2R^{phos} + \beta arr1 + Fab30$  complexes represent 'tail only' and 'fully' (tail + core) engaged complexes, respectively. (d) Bimane fluorescence at emission  $\lambda_{max}$  as measured in c is presented as a bar graph. Data presented in d represent mean  $\pm$  s.e.m. of three independent experiments analysed using one-way ANOVA with Bonferroni post-test (\*\*\* $P < 0.001$ ).





**Figure 3 | Ligand-dependent modulation of core interaction in  $Apo\beta_2V_2R^{phos}$ - $\beta$ arr1-Fab30 complex.** (a) A schematic representation showing that  $Apo\beta_2V_2R^{phos}$  can potentially sample active like conformations and, therefore, might engage core interaction to some extent. Incubation with an inverse agonist is likely to ablate this basal level of core interaction yielding a ‘tail only’ complex while incubation with an agonist stabilizes the core interaction and results in a ‘fully engaged’ complex. (b) *In-vitro* assembly of  $Apo\beta_2V_2R^{phos}$  complex with  $\beta$ arr1 in presence of Fab30 as assessed by ELISA approach. Incubation of this pre-formed complex with inverse agonist or agonist does not alter the physical assembly of the complex. (c) *In-vitro* assembly of  $Apo\beta_2V_2R^{phos}$  complex with  $\beta$ arr1 in presence of Fab30 as measured by coimmunoprecipitation. Similar to ELISA approach, incubation of pre-formed complex with inverse agonist or agonist does not alter the complex assembly. This experiment was repeated three times with identical results and a representative image is shown. (d) Incubation of pre-formed  $Apo\beta_2V_2R^{phos}$  complex with inverse agonist (carazolol) results in an increase in bimane fluorescence suggesting a loss of core binding, yet presumably stabilization of a ‘tail engaged’ complex. On the other hand, incubation of this complex with agonist (BI-167107) results in a further decrease in bimane fluorescence suggesting the engagement of receptor core and, therefore, stabilization of a ‘fully engaged’ complex. (e) Bimane fluorescence at emission  $\lambda_{max}$  as measured in d is presented as a bar graph. (f) Incubation of pre-formed  $Apo\beta_2V_2R^{phos}$  complex with a panel of ligands results in different extent of bimane fluorescence quenching, which directly correlates to the ligand efficacy. (g) Quantification of decrease in bimane fluorescence at emission  $\lambda_{max}$  as measured in f is presented as a bar graph. Data in d and f represent mean of three independent experiments. Data presented in b, e and g represent mean  $\pm$  s.e.m. of three independent experiments and analysed using one-way ANOVA with Bonferroni post-test (\* $P < 0.05$ ; \*\*\* $P < 0.001$ ).

by coimmunoprecipitation and enzyme-linked immunosorbent assay (ELISA) (Supplementary Fig. 4A–C). Strikingly, however, the degree of fluorescence quenching directly mirrors the ligand efficacy for the receptor (Fig. 3f,g). Furthermore, incubation of pre-formed complex with varying doses of the agonist (BI-167107) reveals that degree of fluorescence quenching directly corresponds to the ligand occupancy of the receptor (Supplementary Fig. 4D).

These observations taken together with data presented in Fig. 2c,d confirm that the complexes of  $Inact\beta_2V_2R^{phos}$  and  $Act\beta_2V_2R^{phos}$  with  $\beta$ arr1 represent, partially engaged (‘tail only’) and fully engaged (‘tail + core’) complexes, respectively. It is interesting to note here that we observe a decrease in bimane fluorescence but not a shift in emission  $\lambda_{max}$ . This indicates that the decrease in bimane fluorescence most likely arises from quenching by a tyrosine or a

tryptophan residue on the receptor and not directly from a different environment sensed by the bimane fluorophore<sup>22</sup>.

**Core interaction is dispensable for ERK2 binding.** Activation of ERK MAP kinase has been extensively used as a primary readout of  $\beta$ arr-dependent signalling downstream of GPCRs<sup>23–26</sup>.  $\beta$ arrs directly interact with ERK2 as well as upstream kinases of ERK cascade (c-Raf1 and MEK1) and it is proposed that  $\beta$ arrs act as scaffolds to bring the components of ERK cascade together<sup>27–30</sup>. We first measured the interaction of purified  $\beta$ arr1 with inactive and active ERK2 in the absence or presence of a phosphopeptide corresponding to the carboxyl terminus of the vasopressin receptor (V<sub>2</sub>Rpp). This phosphopeptide mimics the interaction of phosphorylated receptor tail and induces activation of  $\beta$ arrs<sup>31–33</sup>. We observed that  $\beta$ arr1 interacts efficiently with ERK2/pERK2 and this interaction is not altered significantly in the presence of V<sub>2</sub>Rpp (Supplementary Fig. 5). This finding suggests that activation of  $\beta$ arr per se may not be required for its interaction with ERK2 and it prompted us to hypothesize that both, ‘partially’ and ‘fully’ engaged complexes should be able to interact with ERK efficiently. Therefore, in order to test the functional competence of the partially engaged complex, we compared the binding of purified inactive and active ERK2 with fully engaged and partially engaged  $\beta_2$ V<sub>2</sub>R- $\beta$ arr1-ScFv30 complexes by ELISA and coimmunoprecipitation (Fig. 4a–c and Supplementary Fig. 6). Here we used an ScFv variant of Fab 30, referred to as ScFv30 (Supplementary Fig. 6A), to stabilize the  $\beta_2$ V<sub>2</sub>R- $\beta$ arr1 complex in order to minimize any potential clash with ERK binding. Similar to Fab30, ScFv30 also effectively stabilizes  $\beta_2$ V<sub>2</sub>R- $\beta$ arr1 complex (Supplementary Fig. 6B). Interestingly, as presented in Fig. 4b,c (and Supplementary Fig. 6D–G), both <sup>inact</sup> $\beta_2$ V<sub>2</sub>R<sup>phos</sup>- $\beta$ arr1 complex (tail engaged) and <sup>act</sup> $\beta_2$ V<sub>2</sub>R<sup>phos</sup>- $\beta$ arr1 complex (fully engaged) exhibited robust binding to inactive (non-phosphorylated) and active (phosphorylated) ERK2. These data directly suggest that the core interaction in  $\beta_2$ V<sub>2</sub>R- $\beta$ arr1 complex is dispensable for ERK binding. We note that the interaction of ERK2 MAP kinase with <sup>act</sup> $\beta_2$ V<sub>2</sub>R<sup>phos</sup>- $\beta$ arr1 complex is slightly higher than <sup>inact</sup> $\beta_2$ V<sub>2</sub>R<sup>phos</sup>- $\beta$ arr1 complex in the ELISA format and this observation perhaps reflects relatively higher stability of the agonist bound quaternary complex under the experimental conditions.

In order to further corroborate these findings, we utilized a previously described nanobody (referred to as Nb6B9) that selectively recognizes agonist bound  $\beta_2$ AR conformation and represents a G protein mimetic<sup>34</sup>. CDR3 of this nanobody displays a significantly overlapping interface on the receptor with that of the finger loop of  $\beta$ arr1 (Fig. 4d). Therefore, we reasoned that pre-incubation of this nanobody with <sup>act</sup> $\beta_2$ V<sub>2</sub>R<sup>phos</sup> should preclude the finger loop mediated core interaction with  $\beta$ arr1. We first confirmed that binding of Nb6B9 to  $\beta_2$ V<sub>2</sub>R does not affect the assembly of  $\beta_2$ V<sub>2</sub>R- $\beta$ arr1-Fab30 complex (Fig. 4e). We then tested the effect of Nb6B9 on bimane fluorescence in  $\beta_2$ V<sub>2</sub>R- $\beta$ arr1-Fab30 complex. As presented in Fig. 4f, indeed pre-incubation of this nanobody to the receptor followed by addition of  $\beta$ arr1 and Fab30 abolished bimane fluorescence quenching that is observed in the absence of this nanobody. This data suggests that Nb6B9 blocks the core interaction between the  $\beta_2$ V<sub>2</sub>R and  $\beta$ arr1. Interestingly, however, the presence of this nanobody does not affect the interaction of the complex with active and inactive ERK2 MAP kinase (Fig. 4g,h). This observation taken together with the data presented in Fig. 4b,c confirms that the core interaction in  $\beta_2$ V<sub>2</sub>R- $\beta$ arr1 complex is dispensable for ERK binding.


**Core interaction is dispensable for ERK activation.** We next tested whether  $\beta_2$ V<sub>2</sub>R engaged to  $\beta$ arr1 only through the tail interaction is sufficient to trigger ERK activation in cells. As mentioned earlier, chemical cross-linking and structural modelling has identified the third intracellular loop in  $\beta_2$ V<sub>2</sub>R as a major site for the core interaction with  $\beta$ arr1 (Fig. 5a). In particular, Lys<sup>235</sup> on the third intracellular loop of  $\beta_2$ V<sub>2</sub>R cross-links with Lys<sup>77</sup> in the finger loop of  $\beta$ arr1 (Fig. 5a, inset). Furthermore, cross-linking studies and recent crystal structure of rhodopsin-visual arrestin complex has also identified the third intracellular loop as a part of the interface for the core interaction (Fig. 5b). Therefore, we generated a truncated  $\beta_2$ V<sub>2</sub>R construct that harbours deletion of the third intracellular loop ( $\Delta$ 239 – 267; referred to as  $\beta_2$ V<sub>2</sub>R <sup>$\Delta$ ICL3</sup>) (Fig. 5c). Agonist stimulation of HEK-293 cells expressing  $\beta_2$ V<sub>2</sub>R <sup>$\Delta$ ICL3</sup> leads to significant recruitment of  $\beta$ arr1, albeit somewhat weaker than  $\beta_2$ V<sub>2</sub>R, as assessed by confocal microscopy (Fig. 5d) and coimmunoprecipitation experiment (Fig. 5e). This data suggest that the absence of the third intracellular loop and, therefore, the core interaction does not ablate  $\beta$ arr1 binding to the activated receptor in cellular context. In order to further confirm the interaction of  $\beta_2$ V<sub>2</sub>R <sup>$\Delta$ ICL3</sup> with  $\beta$ arr1 and the status of core interaction in its complex with  $\beta$ arr1, we expressed and purified  $\beta_2$ V<sub>2</sub>R <sup>$\Delta$ ICL3</sup> using baculovirus infected Sf9 cells (Supplementary Fig. 3). As presented in Fig. 5f–h, purified  $\beta_2$ V<sub>2</sub>R <sup>$\Delta$ ICL3</sup> formed a stable complex with  $\beta$ arr1 in the presence of Fab30 as evaluated by ELISA and coimmunoprecipitation experiments. Most interestingly,  $\beta_2$ V<sub>2</sub>R <sup>$\Delta$ ICL3</sup> even in the presence of agonist (that is, <sup>act</sup> $\beta_2$ V<sub>2</sub>R <sup>$\Delta$ ICL3-phos</sup>) did not exhibit any bimane fluorescence quenching upon interaction with  $\beta$ arr1 (Fig. 5i,j), indicating the inability of  $\beta_2$ V<sub>2</sub>R <sup>$\Delta$ ICL3</sup> to engage the core interaction with  $\beta$ arr1.

In order to further confirm the dispensability of the core interaction for ERK recruitment, we probed whether a complex of  $\beta_2$ V<sub>2</sub>R <sup>$\Delta$ ICL3</sup> with  $\beta$ arr1 can bind purified pERK2. As presented in Fig. 6a and Supplementary Fig. 7A,  $\beta_2$ V<sub>2</sub>R <sup>$\Delta$ ICL3</sup>- $\beta$ arr1-ScFv30 complex robustly recruited pERK2 and the level of interaction was comparable to that with analogous  $\beta_2$ V<sub>2</sub>R complex. More importantly, stimulation of cells expressing  $\beta_2$ V<sub>2</sub>R <sup>$\Delta$ ICL3</sup> with agonist isoproterenol leads to robust ERK activation similar to  $\beta_2$ V<sub>2</sub>R (Fig. 6b,c). Of particular interest is the ERK activation at late time points (10, 20 and 30 min), which are well established to be mediated by  $\beta$ arr-dependent and G protein independent pathway. These observations taken together with the data presented in Fig. 4 suggest that the core interaction in  $\beta_2$ V<sub>2</sub>R- $\beta$ arr1 complex is dispensable for ERK binding and activation. As mentioned earlier, the chimeric  $\beta_2$ V<sub>2</sub>R behaves like a class B receptor with respect to  $\beta$ arr interaction. Therefore, in order to probe whether the core interaction might be dispensable for class A receptors as well, we generated a native  $\beta_2$ AR construct with truncated third intracellular loop, referred to as  $\beta_2$ AR <sup>$\Delta$ ICL3</sup>, and measured agonist induced ERK activation. Interestingly, we found that similar to  $\beta_2$ V<sub>2</sub>R, truncation of the third intracellular loop in native  $\beta_2$ AR also does not adversely affect ERK activation (Fig. 6d), suggesting that even for class A receptors, the core interaction may not be essential for stimulating ERK response.

In addition to ERK MAP kinase signalling, another key function of  $\beta$ arrs is to promote GPCR internalization via clathrin coated machinery<sup>35–37</sup>. It has been documented earlier that activation of  $\beta$ arrs with isolated V<sub>2</sub>Rpp leads to robust clathrin binding<sup>32,33</sup>. In fact, as presented in Fig. 5d, confocal microscopy of cells expressing  $\beta_2$ V<sub>2</sub>R <sup>$\Delta$ ICL3</sup> revealed that the truncated receptor is capable of internalization as reflected by punctate appearance of  $\beta$ arr1-YFP upon agonist stimulation. In order to further confirm whether core interaction is dispensable

for receptor internalization as well, we first measured the interaction of purified clathrin with partially and fully engaged complexes and observed comparable interaction (Supplementary

Fig. 7B). In addition, we also directly compared agonist-induced internalization of  $\beta_2V_2R$  and  $\beta_2V_2R^{\Delta ICL3}$  by measuring surface levels of the receptor in cells. As presented in Fig. 6e,  $\beta_2V_2R^{\Delta ICL3}$



exhibits robust internalization upon agonist stimulation, even with slightly faster kinetics than  $\beta_2V_2R$ . Again, similar to ERK activation, we observed that  $\beta_2AR^{\Delta ICL3}$  also undergoes robust endocytosis upon agonist stimulation (Fig. 6f). Taken together with the bimane fluorescence data, this observation suggests that both, ERK activation and receptor internalization can be efficiently supported by ‘tail only’ engaged receptor- $\beta$ arr complex in the absence of core interaction.

There is some evidence in the literature that the second intracellular loop, R of DRY motif in particular, of GPCRs might also contribute to receptor- $\beta$ arr interaction<sup>38,39</sup>. Therefore, in order to test if ablating the potential contributions of the second intracellular loop towards the core interaction influences  $\beta$ arr recruitment and signalling, we inserted T4 lysozyme in the second intracellular loop of the  $\beta_2V_2R$  (between Lys<sup>141</sup> and Tyr<sup>142</sup>; construct referred to as  $\beta_2V_2R$ -T4L<sup>ICL2</sup>) (Fig. 7a–d). We reasoned that the bulky T4 lysozyme would separate the receptor core from  $\beta$ arr through steric hindrance while not affecting  $\beta$ arr1 recruitment through the phosphorylated tail. We also tested in parallel  $\beta_2V_2R$  constructs with T4L in the first intracellular loop (T4L inserted between Gln<sup>65</sup> and Thr<sup>66</sup>;  $\beta_2V_2R$ -T4L<sup>ICL1</sup>) and third intracellular loop (T4L inserted between Glu<sup>238</sup> and Glu<sup>268</sup> with deletion of 239–267;  $\beta_2V_2R$ -T4L<sup>ICL3</sup>) (Fig. 7a–d). As presented in Fig. 7e, all these constructs exhibited  $\beta$ arr1 recruitment to the receptor upon agonist stimulation as evaluated by confocal microscopy. More interestingly, these constructs also supported agonist induced ERK activation in cells similar to  $\beta_2V_2R$  and, therefore, indicate that the lack of potential contributions of first and second intracellular loops towards core interaction can also be tolerated for ERK activation.

#### A $\beta$ -arrestin biased ligand does not promote core interaction.

An interesting avenue in GPCR signalling that has emerged recently is the concept of biased agonism<sup>40,41</sup> and for several GPCRs, biased ligands are described that selectively trigger one or the other signalling pathways downstream of the receptor<sup>42</sup>. For perfectly biased  $\beta$ arr biased ligands, there is no coupling of heterotrimeric G proteins and, therefore, no requirement of steric hindrance based desensitization of G protein signalling. We, therefore, hypothesized that a  $\beta$ arr biased ligand may not promote core engagement between the receptor and  $\beta$ arr. Carvedilol has been described as a high-affinity  $\beta$ arr biased ligand for  $\beta_2AR$  and it promotes  $\beta$ arr interaction and ERK activation in the absence of any detectable G protein coupling<sup>43</sup> (Fig. 8a). Carvedilol occupied  $\beta_2V_2R$  (referred to as  $\text{Bias}\beta_2V_2R^{\text{Phos}}$ ) exhibited a robust interaction with  $\beta$ arr1 as assessed by ELISA (Fig. 8b) and coimmunoprecipitation (Fig. 8c). Furthermore,  $\text{Bias}\beta_2V_2R^{\text{Phos}}$ - $\beta$ arr1-Fab30 complex also displayed robust interaction with inactive and active ERK (Fig. 8d,e). Most interestingly, the interaction of  $\text{Bias}\beta_2V_2R^{\text{Phos}}$  with bimane

labelled  $\beta$ arr1 did not result in any detectable quenching of bimane fluorescence (Fig. 8f). These findings indicate that in response to a  $\beta$ arr biased ligand, receptor and  $\beta$ arr might engage only through the phosphorylated carboxyl terminus without any significant involvement of the core interaction.

#### Discussion

Agonist activation results in a conformational change in GPCRs which in turn leads to heterotrimeric G protein coupling and downstream responses. Activated receptors are phosphorylated by GRKs which then promotes the recruitment of  $\beta$ arrs. It is generally believed that binding of  $\beta$ arrs to GPCRs sterically precludes further G protein coupling leading to receptor desensitization<sup>44,45</sup>. In fact, superimposition of  $\beta_2AR$ -G protein complex crystal structure<sup>46</sup> with electron microscopy based architecture of  $\beta_2AR$ - $\beta$ arr1 complex<sup>11</sup> reveals a significantly overlapping interface on the receptor for  $\beta$ arr1 and the  $G\alpha_s$  (Supplementary Fig. 8A). Moreover, crystal structure of rhodopsin with  $G\alpha$  C terminus peptide ( $G\alpha$ CT)<sup>47</sup> and arrestin finger loop peptide<sup>9</sup> has revealed overlapping binding sites for the G protein and arrestin on the intracellular surface of the receptor. These observations indeed support steric hindrance based desensitization mechanism through competition for an overlapping interface on the cytoplasmic surface of the receptor. Interestingly, negative stain EM analysis of the  $\beta_2V_2R$ - $\beta$ arr1 complex revealed a stable intermediate state in the biphasic interaction that represents a complex between  $\beta_2V_2R$  and  $\beta$ arr1 associated solely through the phosphorylated carboxyl terminus of the receptor<sup>11</sup>. Stable isolation and direct visualization of this partially engaged complex underscores the sufficiency of phosphorylated receptor tail for a physical complex formation with  $\beta$ arr and hints at its potential functional significance. Interestingly, crystal structure of pre-activated visual arrestin<sup>48</sup> and  $V_2Rpp$  bound  $\beta$ arr1<sup>31</sup> have revealed major conformational changes compared with basal arrestin conformation. These changes include  $\sim 20$  Å movements of the N- and the C-domain relative to each other and disruption of the polar core. These observations suggest that even partially engaged arrestin might be primed and conformationally competent to initiate at least some of  $\beta$ arr functions. Our data presented here indeed suggest that partially engaged  $\beta_2V_2R$ - $\beta$ arr1 complex associated only through the carboxyl terminus is sufficient to bind both, inactive and active ERK2. Furthermore, a truncated  $\beta_2V_2R$  lacking the 3rd intracellular loop and thereby defective in making core interaction with  $\beta$ arr not only recruits  $\beta$ arr1 in cells but also results in agonist stimulated ERK activation and receptor internalization. Considering these findings, it is tempting to suggest that the core interaction between the GPCR and  $\beta$ arrs might be essential for desensitization through steric hindrance while the tail interaction is sufficient, at least for some


**Figure 4 | Core interaction is dispensable for recruitment of ERK2 MAP kinase.** (a) An ELISA based approach to test the interaction of purified ERK2 with pre-formed  $\beta_2V_2R$ - $\beta$ arr1-ScFv30 complex. Purified ERK2 (inactive or active) is immobilized on polystyrene surface followed by incubation with either the ‘tail only’ engaged or ‘fully’ engaged pre-formed complex. Interaction of ERK with the complex is visualized using HRP-coupled anti-FLAG M2 antibody as a read out of  $\beta_2V_2R$  retention on the plate. (b) Both ‘tail only’ engaged ( $\text{Inact}\beta_2V_2R^{\text{Phos}} + \beta\text{-arr1} + \text{ScFv30}$ ) and ‘fully’ engaged ( $\text{Act}\beta_2V_2R^{\text{Phos}} + \beta\text{-arr1} + \text{ScFv30}$ ) complexes interact with immobilized inactive (non-phosphorylated) ERK2. (c) Similar to inactive ERK2, phosphorylated ERK2 (that is, active) also interacts with both, the ‘tail only’ engaged and ‘fully’ engaged complexes. (d) A previously described conformationally selective nanobody (Nb6B9) against agonist bound  $\beta_2AR$  conformation has an overlapping interface with the core interaction. Structural representation based on superimposition of crystal structure of agonist bound  $\beta_2AR$  and nanobody Nb6B9 (PDB ID:4LDO) and electron microscopy based model of  $\beta_2V_2R$ - $\beta$ arr1 complex. (e) Pre-incubation of  $\text{Act}\beta_2V_2R^{\text{Phos}}$  with purified Nb6B9 does not affect its physical interaction with  $\beta$ arr1. Purified  $\text{Act}\beta_2V_2R^{\text{Phos}}$  was first incubated with a threefold molar excess of Nb6B9 and subsequently used for the assembly of  $\beta_2V_2R$ - $\beta$ arr1-Fab30 complex in ELISA format. (f) Pre-incubation of  $\text{Act}\beta_2V_2R^{\text{Phos}}$  with Nb6B9 abolishes bimane fluorescence quenching observed upon interaction with  $\beta$ arr1 suggesting that presence of Nb6B9 in  $\text{Act}\beta_2AR^{\text{Phos}} + \beta$ arr1 + Fab30 complex converts it to ‘tail only’ engaged complex. (g) Interaction of inactive ERK2 and (h) active ERK2 with Nb6B9 stabilized ‘tail only’ engaged complex as assessed by ELISA, further suggests that the core interaction is dispensable for ERK recruitment. Data presented in **b**, **c**, **e**, **g** and **h** represent mean  $\pm$  s.e.m. of three independent experiments each carried out in duplicate and analysed using one-way ANOVA with Bonferroni post-test (\*\*\* $P < 0.01$ ; \*\*\*\* $P < 0.001$ ).



of the functional outcomes such as ERK binding, activation and receptor internalization (Supplementary Fig. 8B).

Based on their relative patterns of  $\beta$ arr recruitment, GPCRs are broadly categorized as either class A or class B receptors<sup>18</sup>. Class A receptors, such as  $\beta_2$ AR, bind transiently to  $\beta$ arrs and show rapid recycling to the cell surface after internalization. Class B receptors on the other hand, such as  $V_2$ R, exhibit a more robust

interaction with  $\beta$ arrs and show proteosomal degradation. Class B receptors typically harbour phosphorylatable Ser/Thr clusters in their carboxyl terminus while class A receptors appear to primarily have more scattered Ser/Thr residues. It is conceivable that such clusters of Ser/Thr in class B receptors impart a stronger cumulative contribution towards higher affinity for  $\beta$ arrs. Two recent studies using FIAsh based  $\beta$ arr2 sensors suggest distinct



conformational signatures of  $\beta$ arr2 imparted by class A vs class B GPCRs<sup>49,50</sup>. Although we have primarily used a chimeric receptor,  $\beta_2V_2R$  that displays class B profile of  $\beta$ arr recruitment, we also demonstrate that even for a prototypical class A GPCR,  $\beta_2AR$ , core interaction is not essential for ERK activation and internalization. This observation indicates that both, class A and B receptors are capable of undergoing endocytosis and triggering ERK activation when engaged with  $\beta$ arrs only through the phosphorylated carboxyl terminus. Along similar lines, a recent investigation has documented that  $\beta$ arr2 can mediate ERK activation downstream of  $\beta_1AR$  despite a very transient interaction and dissociation from the receptor<sup>51,52</sup>. Going forward, it would be interesting to test additional receptor systems to evaluate the generality of these observations in a broader context.


Constitutive activity of GPCRs refers to the basal level of activation even in the absence of activating ligand. For a number of GPCRs, constitutive activity has been detected with respect to G protein activation and it is thought to arise from the abilities of the receptors to sample active like conformations even in the absence of activating ligands. Here we observe that there is a small but significant core interaction between the Apo-receptor and  $\beta$ arr as assayed by bimane fluorescence spectroscopy (Fig. 3), which is destabilized or stabilized by the incubation of this complex with inverse agonists or agonists, respectively. These findings raise the possibility that some basal level of  $\beta$ arr recruitment might exist in cells even in the absence of stimulating ligand and in fact may be responsible for desensitizing the constitutive receptor activity and some basal level of  $\beta$ arr signalling. Future investigations will be required to carefully probe this aspect of GPCR signalling.

It is important to mention that  $\beta$ arrs mediate and regulate multiple functions downstream of GPCRs. For example,  $\beta$ arrs can scaffold the components of clathrin mediate internalization machinery such as clathrin and AP2 and have a key role in GPCR internalization<sup>35,53</sup>. In addition to ERK MAP kinase,  $\beta$ arrs also scaffold components of other MAP kinase pathways (such as JNK<sup>54,55</sup>, p38) as well as c-Src<sup>56</sup> and Akt<sup>57</sup>. Furthermore, scaffolding of E3 ubiquitin ligases has also emerged as a new functional role of  $\beta$ arrs for GPCRs and non-GPCR membrane proteins<sup>58–60</sup>. Although our data suggest that  $\beta$ arr1 engaged to the receptor only through the phosphorylated carboxyl terminus is competent to recruit and activate ERK MAP kinase and support receptor internalization, it is plausible that core interaction might still be required for some of the other functional aspects of GPCR– $\beta$ arr complex, in addition to receptor desensitization. Further investigations are required to

probe such a scenario where differently engaged GPCR– $\beta$ arr complexes carry out different sub-sets of functions and this might help establish a mechanistic basis for broad functional repertoire and effective functional segregation along the GPCR– $\beta$ arr signalling axis. It should also be noted that even with ICL3 truncated chimeric  $\beta_2V_2R$  or with other class B GPCRs, some transient core interaction can still occur, which escapes detection in bimane fluorescence assay but might still contribute towards some of the functional outcomes.

The concept of biased GPCR signalling and development of biased ligands has refined the general understanding of receptor pharmacology<sup>61–63</sup>. For many GPCRs, biased ligands are proposed to represent better therapeutic potential over currently prescribed ones by virtue of having reduced side effects<sup>42</sup>. However, the mechanistic and structural insights into biased GPCR signalling remains relatively less well defined. It is proposed that biased ligands induce a distinct set of conformations in the receptor than unbiased ligands and these different conformations are subsequently recognized by downstream effectors such as  $\beta$ arrs<sup>11,64</sup>. As a result, effectors also adopt distinct conformations which in turn govern their functional outcome<sup>50,65</sup>. A recent study using unnatural amino acid incorporation and <sup>19</sup>F-NMR on  $\beta$ arr1 has investigated the connection between  $\beta$ arr1 conformation and functional outcome<sup>66</sup>. This study suggests that different phosphopeptides harbouring differential phosphorylation patterns that potentially correspond to a bar-code imparted by different GRKs are capable of inducing distinct conformations in  $\beta$ arr1. These distinct conformations in turn fine-tune the functional outcome of  $\beta$ arr1 such as clathrin binding and c-Src activation<sup>66</sup>. Furthermore, two recent reports using  $\beta$ arr2 conformational sensors also suggest that not only different receptors impose different conformational signature on  $\beta$ arr2, but also ligands of different efficacies (such as unbiased and biased) induce detectably different conformations in  $\beta$ arr2<sup>49,50</sup>. However, it currently remains unknown whether a GPCR– $\beta$ arr complex in response to a biased ligand is conformationally and structurally different than that in response to unbiased ligand. As  $\beta$ arr biased ligands selectively trigger  $\beta$ arr recruitment in the absence of any G protein activation, there is no requirement of desensitization of G protein signalling. Therefore, it is logical to speculate that  $\beta$ arr may not be required to fully engage with the receptor core. Our findings that carvedilol, a  $\beta$ arr biased  $\beta_2AR$  ligand, does not engage core interaction between the receptor and  $\beta$ arr1 in fact supports such a possibility. Although carvedilol has a weak efficacy for  $\beta$ arr-dependent  $\beta_2AR$  signalling, <sup>19</sup>F NMR based analysis of carvedilol bound  $\beta_2AR$ <sup>67</sup> as well as chemical labelling approach<sup>68</sup> has directly demonstrated that it promotes distinct conformational changes in

**Figure 5 | Truncation of the third intracellular loop in  $\beta_2V_2R$  ablates core interaction with  $\beta$ arr1.** (a) Cross-linking experiments and electron microscopy based structural model of  $\beta_2V_2R$ – $\beta$ arr1 complex has identified the third intracellular loop of the  $\beta_2V_2R$  as prominent interface for core interaction through docking of the finger loop of  $\beta$ arr1. Residues that are identified to cross-link with each other in  $\beta_2V_2R$ – $\beta$ arr1 complex are labelled and their side chains are highlighted as space fill model. (b) Cross-linking studies and X-ray crystal structure of rhodopsin-visual arrestin also displays the vicinity of the third intracellular loop in rhodopsin with the finger loop of visual arrestin. (c) Sequence alignment of  $\beta_2V_2R$  and  $\beta_2V_2R^{\Delta ICL3}$  (third intracellular loop truncated receptor) to highlight the deleted amino acids (Gly<sup>238</sup>–Lys<sup>267</sup>) (red box). (d) Confocal microscopy of HEK-293 cells expressing either  $\beta_2V_2R$  or  $\beta_2V_2R^{\Delta ICL3}$  with  $\beta$ -arr1-YFP. Agonist stimulation leads to accumulation of endocytotic vesicles that indicates recruitment of  $\beta$ arr1 to activated receptor. Nuclear staining is shown using 4,6-diamidino-2-phenylindole. Compared with  $\beta_2V_2R$ ,  $\beta_2V_2R^{\Delta ICL3}$  exhibits somewhat weaker recruitment of  $\beta$ arr1 as reflected by less punctate appearance. Scale bar, 10  $\mu$ m. (e) Coimmunoprecipitation of  $\beta_2V_2R^{\Delta ICL3}$  with  $\beta$ arr1 expressed in HEK-293 cells further confirms the recruitment of  $\beta$ arr1 to the truncated receptor upon agonist stimulation. Cells were stimulated with agonist (Isoproterenol, 10  $\mu$ M for 30 min at 37 °C) followed by cross-linking using dithiobis(succinimidyl-propionate) (1 mM for 30 min at room-temperature) and subsequently, receptor– $\beta$ arr1 complex was coimmunoprecipitation using anti-FLAG antibody beads. (f) Assembly of  $\beta_2V_2R^{\Delta ICL3}$  +  $\beta$ -arr1 + Fab30 complex as measured using ELISA approach and (g) coimmunoprecipitation experiment. Similar to  $\beta_2V_2R$ ,  $\beta_2V_2R^{\Delta ICL3}$  also forms a stable complex with  $\beta$ arr1 in the presence of Fab30. (h) Quantification of  $\beta_2V_2R^{\Delta ICL3}$ – $\beta$ arr1 complex formation as assessed by coimmunoprecipitation. (i) Bimane fluorescence spectroscopy on  $\beta_2V_2R^{\Delta ICL3}$  complex reveals the absence of fluorescence quenching even in the presence of agonist and thereby suggests the lack of core interaction. (j) Bimane fluorescence at emission  $\lambda_{max}$  as measured in i is presented as bar graph. Data in f represents mean  $\pm$  s.e.m. of three independent experiments each carried out in duplicate and analysed using one-way ANOVA with Bonferroni post-test (\*\*\*) $P < 0.001$ . Data in g and h represent two independent experiments.



**Figure 6 | Truncation of the third intracellular loop does affect ERK activation and internalization.** (a) Interaction of phosphorylated ERK2 MAP Kinase with β<sub>2</sub>V<sub>2</sub>R<sup>ΔICL3</sup> + Barr1 + ScFv30 complex as assessed by ELISA approach. Similar to β<sub>2</sub>V<sub>2</sub>R, β<sub>2</sub>V<sub>2</sub>R<sup>ΔICL3</sup> also forms stable complexes with phosphorylated ERK2. Data represent mean ± s.e.m. of three independent experiments each carried out in duplicate and analysed using one-way ANOVA with Bonferroni post-test (\*\*\*P < 0.001). (b) Agonist induced activation of ERK1/2 MAP kinase for β<sub>2</sub>V<sub>2</sub>R and β<sub>2</sub>V<sub>2</sub>R<sup>ΔICL3</sup> shows a similar temporal pattern suggesting that truncation of the third intracellular loop, and, therefore, ablation of the core interaction, does not significantly affect ERK activation. The experiment was repeated four times with identical results and a representative image is shown. (c) Quantification of the ERK activation data presented as mean ± s.e.m. of four independent experiments. (d) Agonist induced activation of ERK1/2 MAP kinase downstream of β<sub>2</sub>AR<sup>WT</sup> and β<sub>2</sub>AR<sup>ΔICL3</sup> also reveals similar pattern suggesting the dispensability of the core interaction even for class A receptors. A representative image and quantitation of seven independent experiments are shown. (e) Similar to ERK activation, agonist induced internalization of β<sub>2</sub>V<sub>2</sub>R<sup>ΔICL3</sup> also exhibits a comparable pattern to β<sub>2</sub>V<sub>2</sub>R<sup>WT</sup> albeit with an increased kinetics. (f) β<sub>2</sub>AR<sup>ΔICL3</sup> also undergoes robust internalization upon agonist stimulation similar to β<sub>2</sub>AR<sup>WT</sup>. Data in e and f represent six independent experiments each carried out in duplicate and presented as mean ± s.e.m.

the receptor compared with unbiased agonists or inverse agonists. However, further experimentation with other GPCRs that have more efficacious biased ligand is desirable to probe the generalization of this observation.

In conclusion, our findings reveal a previously unknown aspect of GPCR–βarr interaction and provide a potential basis for broad functional repertoire of this signalling axis. In contrast with generally anticipated notion, we demonstrate that partially



engaged GPCR- $\beta$ arr complex is functionally competent with respect to supporting receptor internalization, and recruitment and activation of ERK MAP Kinase. Our data also suggest that  $\beta$ arr biased ligands may not engage the receptor core with  $\beta$ arr and, therefore, identify a key mechanistic insight in to biased agonism. It would be very interesting to investigate in future

whether other conserved  $\beta$ arr functions might also be carried out through partial engagement with the activated GPCRs.

## Methods

**General reagents and protein expression.** General chemicals and cell culture consumables were purchased from Sigma-Aldrich or local vendors unless specified otherwise. Codon optimized  $\beta$ arr1 gene was synthesized (Genscript), sub-cloned in to pGEX4T3 vector (purchased from GE), expressed in *E. coli* (BL21) and purified using Glutathione Sepharose affinity resin<sup>33</sup>. Codon optimized Fab30 open reading frame was synthesized (Genscript) based on published crystal structure (PDB ID: 4JQI) (ref. 31), expressed and purified in M55244 strain of *E. coli* (purchased from American Type Culture Collection)<sup>69</sup>. As an alternative strategy, the coding regions for the light and heavy chains of Fab30 were cloned in pETDuet-1 vector (Novagen), expressed in BL21 (DE3) cells (NEB) with 0.5 mM isopropyl- $\beta$ -D-thiogalactoside induction at 18 °C for 12–16 h (Supplementary Fig. 1). Subsequently, Fab30 was purified from total lysate on Protein L resin (purchased from GE)<sup>69</sup>. The coding region of nanobody Nb6B9 was synthesized based on previously published crystal structure (PDB ID: 4LDO) (ref. 34) and it was expressed in *E. coli* (Rosetta) (NEB) and purified using Ni-NTA affinity chromatography<sup>34</sup>. Coding region of  $\beta$ arr1-Cys<sup>68</sup> was synthesized (Genscript) and cloned in pGEX4T3 vector followed by expression in *E. coli* (BL21) and purification on Glutathione Sepharose affinity resin (Clontech).


Coding region of human ERK2 and constitutively active MEK1 (R4F) were synthesized (Genscript), cloned in pGEX4T3 vector and expressed in *E. coli* ShuffleT7 express cells (NEB). Protein expression was induced at OD<sub>600</sub> 0.6–0.8 with 0.2 mM isopropyl- $\beta$ -D-thiogalactoside at 16 °C for 12–16 h. Cell pellets were resuspended in lysis buffer (25 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM phenylmethyl sulphonyl fluoride, 0.25 mM dithiothreitol and lysozyme for 1 h at 4 °C. Cell suspension was sonicated, centrifuged and then loaded on to a pre-equilibrated Glutathione-Sepharose resin (GE). After overnight binding at 4 °C, beads were washed extensively and then proteins were eluted using thrombin protease (Sigma or Merck). For ERK2 phosphorylation, a reaction containing inactive ERK2 and constitutive active MEK1 (R4F) in phosphorylation buffer (20 mM HEPES, pH 7.0, 5 mM MgCl<sub>2</sub>, 50 mM NaCl, 1 mM dithiothreitol, 100–200 nM ATP) was prepared and incubated for 1 h at 30 °C. The reaction was quenched by addition of stop buffer (50 mM Tris pH 7.5, 18 mM EDTA), followed by a buffer exchange step on a PD10 column. Phosphorylation of ERK2 was validated by western blotting with phospho-ERK antibody (CST, catalog number. 9101; 1:5,000 dilution).

Open reading frames of FLAG- $\beta_2V_2R$  chimeric receptor and GRK2<sup>CAAX</sup> were synthesized (Genscript) and baculovirus stocks were generated using standard protocols (Expression Systems). FLAG- $\beta_2V_2R$  and GRK2<sup>CAAX</sup> were co-expressed in *Sf9* cells (purchased from Expression Systems) and cultured in ESF921 media (Expression Systems) and 60–66 h post-infection; cells were stimulated with indicated ligand, harvested and lysed by glass douncing. Subsequently, cells were solubilized using 0.5% (w/v) maltose neopentyl glycol (MNG, purchased from Anatrace) and purified on anti-FLAG M1 affinity resin (Sigma). Purified protein samples were either used fresh in the experiments or flash-frozen in small aliquots after addition of 10–20% glycerol and stored at –80 °C until further use.


**ELISA based assembly of  $\beta_2V_2R$ - $\beta$ arr1-Fab30 complex.** For ELISA based *in-vitro* assembly of  $\beta_2V_2R$ - $\beta$ arr1-Fab/ScFv30 complexes, purified Fab/ScFv30 (in 20 mM HEPES, pH 7.4, 100 mM NaCl) was first immobilized on 96 well MaxiSorp polystyrene plates (Nunc) at room temperature for 1 h. Afterwards, potential non-specific binding sites in the wells were blocked by incubation with 1% BSA at room temperature for 1 h. Subsequently, mixture of ligand stimulated cell lysate (or purified receptor) was added to the wells and incubated at room temperature for 1 h. Wells were washed extensively using 20 mM HEPES, pH 7.4, 100 mM NaCl, 0.01% MNG and then incubated with 1:2,000 dilution of HRP-coupled anti-FLAG M2 antibody (Sigma, catalog number A8592). After 1 h incubation, wells were extensively washed and assembly of the complex was visualized by adding 3,3',5,5'-tetramethylbenzidine (TMB) ELISA (Genscript or Thermo). Colorimetric reaction was stopped by adding 1M H<sub>2</sub>SO<sub>4</sub> and absorbance

## Figure 7 | Blocking the potential contribution of intracellular loops does not affect ERK activation.

Schematic illustration of  $\beta_2V_2R$  constructs with T4 lysozyme insertion in (a) intracellular loop 1 between Gln<sup>65</sup> and Thr<sup>66</sup> (b) intracellular loop 2 between Lys<sup>141</sup> and Tyr<sup>142</sup> and (c) intracellular loop 3 between Glu<sup>238</sup> and Glu<sup>268</sup> with deletion of 239–267. (d) Expression of  $\beta_2V_2R$ -T4L constructs in transfected HEK-293 cells as visualized by western blotting using N-terminal FLAG tag. (e) Agonist induced  $\beta$ arr1 recruitment to  $\beta_2V_2R$ -T4L constructs as visualized by confocal microscopy in HEK-293 cells expressing  $\beta$ arr1-YFP. Scale bar, 10  $\mu$ m. (f) Agonist (Isoproterenol, 10  $\mu$ M) induced ERK1/2 activation in HEK-293 cells expressing  $\beta_2V_2R$ -T4L constructs at indicated time points. Data in f show a representative image of three independent experiments.







**Figure 8 | A barr biased ligand of  $\beta_2AR$  does not promote core interaction with  $\beta_2V_2R$ .** (a) Carvedilol is a high-affinity  $\beta_2AR$  biased ligand and it selectively promotes  $\beta_2AR$  binding and ERK activation in the absence of any detectable G protein coupling. (b) Carvedilol bound and phosphorylated  $\beta_2V_2R$  (referred to as  $Bias\beta_2V_2R^{phos}$  generated through incubation of  $Act\beta_2V_2R^{phos}$  with tenfold molar excess of carvedilol) exhibits a robust interaction with  $\beta_2V_2R$  in the presence of Fab30 as assessed by ELISA. Purified Fab30 was immobilized and then incubated with  $\beta_2V_2R$  and either  $Bias\beta_2V_2R^{phos}$  or  $Act\beta_2V_2R^{phos}$ . Formation of complex was detected using anti-FLAG M2 antibody. (c) Formation of  $\beta_2V_2R$  complex with  $Bias\beta_2V_2R^{phos}$  in the presence of Fab30 as assessed by coimmunoprecipitation. The experiment was repeated three times with identical results and a representative image is shown. Quantification of the data is shown as bar graph. (d) Interaction of  $Bias\beta_2V_2R^{phos}$  +  $\beta_2V_2R$  + ScFv30 and  $Act\beta_2V_2R^{phos}$  +  $\beta_2V_2R$  + ScFv30 complexes with inactive and (e) active ERK2. Purified ERK2 was immobilized followed by incubation with pre-formed complexes and detection using HRP-coupled anti-FLAG M2 antibody. (f) Interaction of  $Bias\beta_2V_2R^{phos}$  with  $\beta_2V_2R$  does not lead to a detectable decrease in bimane fluorescence suggesting the lack of core interaction.  $Act\beta_2V_2R^{phos}$  was first incubated with tenfold molar excess of carvedilol or BI-167107 to obtain  $Bias\beta_2V_2R^{phos}$  and  $Act\beta_2V_2R^{phos}$ , respectively. Subsequently, these receptor preparations were incubated with bimane labelled  $\beta_2V_2R$  and Fab 30 to form a complex followed by fluorescence scanning in the wavelength range indicated on the graph. The data represent an average of three independent experiments. Data presented in b, d and e represent mean  $\pm$  s.e.m. of at least three independent experiments each carried out in duplicate and analysed using one-way ANOVA with Bonferroni post-test (\*\* $P < 0.01$ ; \*\*\* $P < 0.001$ ).

was measured at 450 nm using a Victor X4 plate reader (Perkin-Elmer). All the ELISA data are normalized with respect to the signal for  $Act\beta_2V_2R^{phos}$  complex which is treated as 100%.

For dephosphorylation experiment, cell lysate was incubated with  $\lambda$ -phosphatase (NEB) at 25 °C for 2 h and subsequently used for *in-vitro* assembly of the complex. Fab CTL represents a random Fab taken from the library as a negative control. For dose response ELISA experiment, different amounts of  $\beta_2V_2R$ - $\beta_2V_2R$  mixture were added to the Fab30 coated anchor surface followed by blocking of non-specific binding surface and complex detection.

**Bimane fluorescence spectroscopy.** Purified  $\beta_2V_2R^{L68C}$  was buffer exchanged in 20 mM Hepes, 150 mM NaCl, pH 7.5 buffer and concentrated to  $\sim 2.0$  mg  $ml^{-1}$ . It was incubated with 10-fold molar excess of monobromobimane (mBB, Sigma-Aldrich) on ice for 1 h. Subsequently, the sample was centrifuged at 100,000g for 30 min to remove aggregates and then unreacted mBB was separated on a PD10 desalting column (GE Healthcare). Labelled protein was either used in bimane fluorescence experiment right away or flash frozen with 20% glycerol for

later usage. Labelling efficiency of  $\beta_2V_2R^{L68C}$  under these conditions was measured to be about 85%. For fluorescence experiments, mBB labelled  $\beta_2V_2R^{L68C}$  was used at an approximate final concentration of 2  $\mu M$  and it was mixed with threefold molar excess (6  $\mu M$ ) of purified  $\beta_2V_2R$  and Fab30 for 60 min at room temperature (25 °C). For the experiments presented in Fig. 2 and Fig. 8, purified  $Act\beta_2V_2R^{phos}$  was pre-incubated with 5–10 fold molar excess (30–60  $\mu M$ ) of respective ligands (30 min at 25 °C) before mixing it with  $\beta_2V_2R$  and Fab30. For the experiments presented in Fig. 3, the complex of  $Act\beta_2V_2R^{phos}$ - $\beta_2V_2R$ -Fab30 (6  $\mu M$ :2  $\mu M$ :2  $\mu M$ ) was allowed to form at 25 °C followed by addition of 5–10 fold molar excess of ligand (30–60  $\mu M$ ) and an additional 30 min incubation at 25 °C. Fluorescence scanning analysis was performed using Fluorimeter (Perkin Elmer, USA model LS-55) in photon counting mode by setting the excitation and emission band pass filter of 5 nm. For emission scan, excitation was set at 397 nm and emission was measured from 415 nm to 600 nm with scan speed of 50 nm  $min^{-1}$ . Bimane fluorescence intensities in each experiment are normalized with respect to  $\beta_2V_2R$  + Fab30 condition, which is treated as 100%. Fluorescence intensity was also corrected for background fluorescence from buffer and protein in all experiments and each experiment was repeated at least three times.

**ERK assay and confocal microscopy.** HEK-293 cells (purchased from American Type Culture Collection) were cultured in Dulbecco's modified Eagle's complete media (Sigma) supplemented with 10% fetal bovine serum (Thermo Scientific) and 1% penicillin-streptomycin at 37 °C under 5% CO<sub>2</sub>. For protein expression, cells were transfected with indicated plasmids using PEI (Polyethylenimine) as the transfection reagent at a DNA to PEI ratio of 1:3 (7 µg of DNA mixed with 21 µl of PEI). Cells were serum starved for 4–12 h and then stimulated with appropriate ligands as indicated in the figure legends.

For cross-linking of  $\beta_2V_2R^{AICL3}$  and  $\betaarr1$ , Carazolol and BI-167107 stimulated HEK-293 cells were resuspended in buffer containing 20 mM HEPES pH 7.4, 100 mM NaCl, 1 × PhosStop (Roche) and 1 × complete protease inhibitor (Sigma). Cells were lysed by dounce homogenization. For cross-linking, 1 mM dithiobis(succinimidyl-propionate) (Sigma) in dimethylsulphoxide was added from 100 mM stock and lysate was tumbled at room temperature for 30 min. The reaction was quenched by adding 1M Tris buffer pH 8.0 and 1% (v/v) MNG was added for solubilization and tumbled for 3 h at 4 °C. Following solubilization, lysate was centrifuged at 21,130g for 30 min. The clear supernatant was collected in separate tube and freshly equilibrated M1 FLAG beads were added for immunoprecipitation. Coimmunoprecipitated  $\betaarr$  and  $\beta_2V_2R$  were detected by western blotting rabbit mAb anti- $\betaarr$  antibody (CST, 1:1,000, catalog number D24H9) and HRP-coupled mouse anti-FLAG M2 mAb (Sigma, 1:1,000). Blots were developed on Chemidoc (Bio-Rad) and subsequently quantified by ImageLab software (Bio-Rad).

For ERK assay, transfected cells were seeded in to six-well plates (Corning), serum starved for 12 h and then stimulated with 10 µM Isoproterenol (Sigma-Aldrich) for indicated time points. Subsequently, the cells were lysed in 200 µl of 2 × SDS loading buffer, sonicated and loaded on to 12% SDS-polyacrylamide gel electrophoresis. Western blotting was performed to observe the phosphorylation of ERK1/2. The bands were transferred on PVDF membrane (BioRad). The membrane was blocked with 5% BSA (SRL) for 1 h and then probed with anti-pERK primary antibody (CST, catalog number. 9101; 1:5,000 dilution) overnight at 4 °C followed by 1 h incubation with anti-rabbit IgG secondary antibody (Genscript, catalog number. A00098) at room temperature. The membrane was then washed with 1 × TBST thrice and developed using Chemi Doc (BioRad). The anti-pERK antibody was stripped-off using 1X stripping buffer and then reprobed with anti-tERK antibody (CST, catalog number. 9102 and 4695; 1:5,000 dilution).

For confocal microscopy, transfected HEK-293 cells were seeded onto 0.001% poly-L-lysine coated glass coverslips and serum starved for 4 h. Cells were then stimulated with 10 µM Isoproterenol for indicated time points, fixed using 4% paraformaldehyde and permeabilized with 0.05% Triton-X-100. For nuclear staining, 0.5 µg ml<sup>-1</sup> of 4,6-diamidino-2-phenylindole solution (Sigma) was added to fixed cells. After final washing with PBS, coverslips were mounted on to glass slides using VectaShield H-1,000 mounting medium (VectaShield), allowed to air dry for 15 min and then imaged using LSM780NLO confocal microscope (Carl Zeiss).

**Coimmunoprecipitation experiments.** In order to assess the formation of  $\beta_2V_2R$ - $\betaarr1$  complex in solution by coimmunoprecipitation, purified  $\beta_2V_2R$  (2.5 µg) was mixed with purified  $\betaarr1$  (2.5 or 5 µg) and Fab30 (2.5 µg) and incubated at room-temperature for 1 h. Subsequently, 20 µl of protein L beads (Capto L, GE Healthcare) were added and the mixture was allowed to tumble at room-temperature for additional 1 h. Afterwards, beads were washed three times with washing buffer (20 mM Hepes, pH 7.4, 150 mM NaCl, 0.01% MNG) and eluted with SDS loading buffer. Eluted samples were separated by 12% SDS-polyacrylamide gel electrophoresis and probed using HRP-coupled anti-FLAG M2 antibody (Sigma, 1:2,000) and HRP-coupled protein L (GenScript, 1:2,000; catalog number M00098) by western blotting.

In order to measure binding of ERK2 with pre-formed complex, purified GST-ERK2 (or GST-pERK2) (6 µg) was immobilized on freshly equilibrated GS beads (1 h at room-temperature) and washed once with washing buffer to remove unbound GST-ERK2. Subsequently, beads were incubated (1 h at room-temperature) with pre-formed  $\beta_2V_2R$ - $\betaarr1$ -ScFv30 complex (4 µg:4 µg:5 µg) followed with three washes. Afterwards, bound samples were eluted in SDS loading buffer and probed by western blotting using HRP-coupled anti-FLAG M2 antibody. Purified GST was used as a control for non-specific binding of the complex to GS beads. Quantification of coIP data is normalized with respect to  $Act\beta_2V_2R^{phos}$ , which is treated as 100%.

**Receptor internalization assay.** HEK-293 cells expressing  $\beta_2V_2R$  and  $\beta_2V_2R^{AICL3}$  seeded in to 24-well plates at a density of 300,000 cells per well and serum starved for 2 h. Cells were stimulated with 10 µM isoproterenol at specified time points followed by three washes with ice cold tris-buffered saline (TBS) and subsequently fixed with 4% (w/v) paraformaldehyde for 20 min on ice. Cells were again washed with TBS and blocked with TBS + 1%(w/v) BSA for 1 h at room temperature. Cells were then incubated with HRP-coupled anti-FLAG M2 antibody (Sigma) at a dilution of 1:1,000 in TBS + 1%BSA for 1 h at room temperature. Afterwards, cells were washed with TBS + 1%(w/v) BSA three times and incubated with 200 µl 3,3',5,5'-tetramethylbenzidine (TMB) per well for visualizing surface receptor expression. Reaction was stopped by transferring 100 µl of developed

solution to a 96-well plate already containing 100 µl of 1M H<sub>2</sub>SO<sub>4</sub>. Plates were read at 450 nm in a microplate reader (Victor X4). For measuring total protein (for normalization), cells were washed with TBS and 200 µl of 0.2% (w/v) Janus green stain was added per well and incubated for 10 min. Subsequently, cells were destained with water until excess dye was removed and colour was developed by adding 800 µl of 0.5 M HCl per well. One-hundred microlitres of solution was transferred in 96-well plate and read at 595 nm in a multi-plate reader. The values were normalized by dividing A<sub>450</sub> reading with A<sub>595</sub> reading.

**Data analysis.** All the data were plotted using GraphPad Prism software and analysed as indicated in the figure legends. For statistical analysis, we used one-way ANOVA with Bonferroni post-test. Uncropped images of key experiments are presented in the Supplementary Fig. 9.

**Data availability.** The crystal structures of Fab30 and nanobody Nb6B9 bound to  $\beta$ -arrestin were obtained from PDB using accession codes 4JQI and 4LDO, respectively. The data that support the findings of this study are available from the corresponding author upon reasonable request.

## References

- Bjarnadottir, T. K. *et al.* Comprehensive repertoire and phylogenetic analysis of the G protein-coupled receptors in human and mouse. *Genomics* **88**, 263–273 (2006).
- Bockaert, J. & Pin, J. P. Molecular tinkering of G protein-coupled receptors: an evolutionary success. *EMBO J.* **18**, 1723–1729 (1999).
- DeWire, S. M., Ahn, S., Lefkowitz, R. J. & Shenoy, S. K. Beta-arrestins and cell signaling. *Annu. Rev. Physiol.* **69**, 483–510 (2007).
- Ghosh, E., Kumari, P., Jaiman, D. & Shukla, A. K. Methodological advances: the unsung heroes of the GPCR structural revolution. *Nat. Rev. Mol. Cell Biol.* **16**, 69–81 (2015).
- Sommer, M. E., Farrens, D. L., McDowell, J. H., Weber, L. A. & Smith, W. C. Dynamics of arrestin-rhodopsin interactions: loop movement is involved in arrestin activation and receptor binding. *J. Biol. Chem.* **282**, 25560–25568 (2007).
- Sommer, M. E., Hofmann, K. P. & Heck, M. Distinct loops in arrestin differentially regulate ligand binding within the GPCR opsin. *Nat. Commun.* **3**, 995 (2012).
- Kim, M. *et al.* Conformation of receptor-bound visual arrestin. *Proc. Natl Acad. Sci. USA* **109**, 18407–18412 (2012).
- Hanson, S. M. *et al.* Differential interaction of spin-labeled arrestin with inactive and active phosphorhodopsin. *Proc. Natl Acad. Sci. USA* **103**, 4900–4905 (2006).
- Szczepek, M. *et al.* Crystal structure of a common GPCR-binding interface for G protein and arrestin. *Nat. Commun.* **5**, 4801 (2014).
- Kang, Y. *et al.* Crystal structure of rhodopsin bound to arrestin by femtosecond X-ray laser. *Nature* **523**, 561–567 (2015).
- Shukla, A. K. *et al.* Visualization of arrestin recruitment by a G-protein-coupled receptor. *Nature* **512**, 218–222 (2014).
- Xiao, K. *et al.* Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). *Proc. Natl Acad. Sci. USA* **107**, 15299–15304 (2010).
- Xiao, K. *et al.* Functional specialization of beta-arrestin interactions revealed by proteomic analysis. *Proc. Natl Acad. Sci. USA* **104**, 12011–12016 (2007).
- Srivastava, A., Gupta, B., Gupta, C. & Shukla, A. K. Emerging functional divergence of beta-arrestin isoforms in GPCR function. *Trends Endocrinol. Metab.* **26**, 628–642 (2015).
- Gurevich, V. V. & Gurevich, E. V. Structural determinants of arrestin functions. *Prog. Mol. Biol. Transl. Sci.* **118**, 57–92 (2013).
- Ostermaier, M. K., Schertler, G. F. & Standfuss, J. Molecular mechanism of phosphorylation-dependent arrestin activation. *Curr. Opin. Struct. Biol.* **29**, 143–151 (2014).
- Gurevich, V. V. & Gurevich, E. V. The molecular acrobatics of arrestin activation. *Trends Pharmacol. Sci.* **25**, 105–111 (2004).
- Oakley, R. H., Laporte, S. A., Holt, J. A., Caron, M. G. & Barak, L. S. Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors. *J. Biol. Chem.* **275**, 17201–17210 (2000).
- Sommer, M. E., Smith, W. C. & Farrens, D. L. Dynamics of arrestin-rhodopsin interactions: arrestin and retinal release are directly linked events. *J. Biol. Chem.* **280**, 6861–6871 (2005).
- Sommer, M. E., Smith, W. C. & Farrens, D. L. Dynamics of arrestin-rhodopsin interactions: acidic phospholipids enable binding of arrestin to purified rhodopsin in detergent. *J. Biol. Chem.* **281**, 9407–9417 (2006).
- Feuerstein, S. E. *et al.* Helix formation in arrestin accompanies recognition of photoactivated rhodopsin. *Biochemistry* **48**, 10733–10742 (2009).
- Sinha, A., Jones Brunette, A. M., Fay, J. F., Schafer, C. T. & Farrens, D. L. Rhodopsin TM6 can interact with two separate and distinct sites on

- arrestin: evidence for structural plasticity and multiple docking modes in arrestin-rhodopsin binding. *Biochemistry* **53**, 3294–3307 (2014).
23. Azzi, M. *et al.* Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. *Proc. Natl Acad. Sci. USA* **100**, 11406–11411 (2003).
  24. Ahn, S., Shenoy, S. K., Wei, H. & Lefkowitz, R. J. Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. *J. Biol. Chem.* **279**, 35518–35525 (2004).
  25. Shenoy, S. K. *et al.* beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor. *J. Biol. Chem.* **281**, 1261–1273 (2006).
  26. Wei, H. *et al.* Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. *Proc. Natl Acad. Sci. USA* **100**, 10782–10787 (2003).
  27. Coffa, S. *et al.* The effect of arrestin conformation on the recruitment of c-Raf1, MEK1, and ERK1/2 activation. *PLoS ONE* **6**, e28723 (2011).
  28. Luttrell, L. M. *et al.* Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds. *Proc. Natl Acad. Sci. USA* **98**, 2449–2454 (2001).
  29. Luttrell, L. M. & Lefkowitz, R. J. The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. *J. Cell Sci.* **115**, 455–465 (2002).
  30. Lefkowitz, R. J. & Shenoy, S. K. Transduction of receptor signals by beta-arrestins. *Science* **308**, 512–517 (2005).
  31. Shukla, A. K. *et al.* Structure of active beta-arrestin-1 bound to a G-protein-coupled receptor phosphopeptide. *Nature* **497**, 137–141 (2013).
  32. Xiao, K., Shenoy, S. K., Nobles, K. & Lefkowitz, R. J. Activation-dependent conformational changes in {beta}-arrestin 2. *J. Biol. Chem.* **279**, 55744–55753 (2004).
  33. Nobles, K. N., Guan, Z., Xiao, K., Oas, T. G. & Lefkowitz, R. J. The active conformation of beta-arrestin1: direct evidence for the phosphate sensor in the N-domain and conformational differences in the active states of beta-arrestins1 and -2. *J. Biol. Chem.* **282**, 21370–21381 (2007).
  34. Ring, A. M. *et al.* Adrenaline-activated structure of beta2-adrenoceptor stabilized by an engineered nanobody. *Nature* **502**, 575–579 (2013).
  35. Goodman, Jr O. B. *et al.* Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor. *Nature* **383**, 447–450 (1996).
  36. Goodman, Jr O. B., Krupnick, J. G., Gurevich, V. V., Benovic, J. L. & Keen, J. H. Arrestin/clathrin interaction. Localization of the arrestin binding locus to the clathrin terminal domain. *J. Biol. Chem.* **272**, 15017–15022 (1997).
  37. Krupnick, J. G., Goodman, O. B. Jr, Keen, J. H. & Benovic, J. L. Arrestin/clathrin interaction. Localization of the clathrin binding domain of nonvisual arrestins to the carboxy terminus. *J. Biol. Chem.* **272**, 15011–15016 (1997).
  38. Kim, K. M. & Caron, M. G. Complementary roles of the DRY motif and C-terminus tail of GPCRS for G protein coupling and beta-arrestin interaction. *Biochem. Biophys. Res. Commun.* **366**, 42–47 (2008).
  39. Marion, S., Oakley, R. H., Kim, K. M., Caron, M. G. & Barak, L. S. A beta-arrestin binding determinant common to the second intracellular loops of rhodopsin family G protein-coupled receptors. *J. Biol. Chem.* **281**, 2932–2938 (2006).
  40. Shukla, A. K., Xiao, K. & Lefkowitz, R. J. Emerging paradigms of beta-arrestin-dependent seven transmembrane receptor signaling. *Trends Biochem. Sci.* **36**, 457–469 (2011).
  41. Violin, J. D. & Lefkowitz, R. J. Beta-arrestin-biased ligands at seven-transmembrane receptors. *Trends Pharmacol. Sci.* **28**, 416–422 (2007).
  42. Whalen, E. J., Rajagopal, S. & Lefkowitz, R. J. Therapeutic potential of beta-arrestin- and G protein-biased agonists. *Trends Mol. Med.* **17**, 126–139 (2011).
  43. Wisler, J. W. *et al.* A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. *Proc. Natl Acad. Sci. USA* **104**, 16657–16662 (2007).
  44. Pierce, K. L. & Lefkowitz, R. J. Classical and new roles of beta-arrestins in the regulation of G-protein-coupled receptors. *Nat. Rev. Neurosci.* **2**, 727–733 (2001).
  45. Pierce, K. L., Premont, R. T. & Lefkowitz, R. J. Seven-transmembrane receptors. *Nat. Rev. Mol. Cell Biol.* **3**, 639–650 (2002).
  46. Rasmussen, S. G. *et al.* Crystal structure of the beta2 adrenergic receptor-Gs protein complex. *Nature* **477**, 549–555 (2011).
  47. Scheerer, P. *et al.* Crystal structure of opsin in its G-protein-interacting conformation. *Nature* **455**, 497–502 (2008).
  48. Kim, Y. J. *et al.* Crystal structure of pre-activated arrestin p44. *Nature* **497**, 142–146 (2013).
  49. Nuber, S. *et al.* beta-Arrestin biosensors reveal a rapid, receptor-dependent activation/deactivation cycle. *Nature* **531**, 661–664 (2016).
  50. Lee, M. H. *et al.* The conformational signature of beta-arrestin2 predicts its trafficking and signalling functions. *Nature* **531**, 665–668 (2016).
  51. Ranjan, R., Gupta, P. & Shukla, A. K. GPCR Signaling: beta-arrestins Kiss and Remember. *Curr. Biol.* **26**, R285–R288 (2016).
  52. Eichel, K., Jullie, D. & von Zastrow, M. beta-Arrestin drives MAP kinase signalling from clathrin-coated structures after GPCR dissociation. *Nat. Cell Biol.* **18**, 303–310 (2016).
  53. Goodman, O. B. Jr *et al.* Role of arrestins in G-protein-coupled receptor endocytosis. *Adv. Pharmacol.* **42**, 429–433 (1998).
  54. Zhan, X., Kook, S., Gurevich, E. V. & Gurevich, V. V. Arrestin-dependent activation of JNK family kinases. *Handb. Exp. Pharmacol.* **219**, 259–280 (2014).
  55. McDonald, P. H. *et al.* Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. *Science* **290**, 1574–1577 (2000).
  56. Luttrell, L. M. *et al.* Beta-arrestin-dependent formation of beta2 adrenergic receptor-*Src* protein kinase complexes. *Science* **283**, 655–661 (1999).
  57. Beaulieu, J. M. *et al.* An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. *Cell* **122**, 261–273 (2005).
  58. Shenoy, S. K. & Lefkowitz, R. J. beta-Arrestin-mediated receptor trafficking and signal transduction. *Trends Pharmacol. Sci.* **32**, 521–533 (2011).
  59. Shukla, A. K. *et al.* Arresting a transient receptor potential (TRP) channel: beta-arrestin 1 mediates ubiquitination and functional down-regulation of TRPV4. *J. Biol. Chem.* **285**, 30115–30125 (2010).
  60. Marchese, A. & Trejo, J. Ubiquitin-dependent regulation of G protein-coupled receptor trafficking and signaling. *Cell. Signal.* **25**, 707–716 (2013).
  61. Kenakin, T. & Christopoulos, A. Signalling bias in new drug discovery: detection, quantification and therapeutic impact. *Nat. Rev. Drug Discov.* **12**, 205–216 (2013).
  62. Onaran, H. O., Rajagopal, S. & Costa, T. What is biased efficacy? defining the relationship between intrinsic efficacy and free energy coupling. *Trends Pharmacol. Sci.* **35**, 639–647 (2014).
  63. Shukla, A. K., Singh, G. & Ghosh, E. Emerging structural insights into biased GPCR signaling. *Trends Biochem. Sci.* **39**, 594–602 (2014).
  64. Rajagopal, S., Rajagopal, K. & Lefkowitz, R. J. Teaching old receptors new tricks: biasing seven-transmembrane receptors. *Nat. Rev. Drug Discov.* **9**, 373–386 (2010).
  65. Shukla, A. K. *et al.* Distinct conformational changes in beta-arrestin report biased agonism at seven-transmembrane receptors. *Proc. Natl Acad. Sci. USA* **105**, 9988–9993 (2008).
  66. Yang, F. *et al.* Phospho-selective mechanisms of arrestin conformations and functions revealed by unnatural amino acid incorporation and (19)F-NMR. *Nat. Commun.* **6**, 8202 (2015).
  67. Liu, J. J., Horst, R., Katritch, V., Stevens, R. C. & Wuthrich, K. Biased signaling pathways in beta2-adrenergic receptor characterized by 19F-NMR. *Science* **335**, 1106–1110 (2012).
  68. Khsai, A. W. *et al.* Multiple ligand-specific conformations of the beta2-adrenergic receptor. *Nat. Chem. Biol.* **7**, 692–700 (2011).
  69. Paduch, M. *et al.* Generating conformation-specific synthetic antibodies to trap proteins in selected functional states. *Methods* **60**, 3–14 (2013).

## Acknowledgements

We thank the members of Dr Shukla's laboratory for scintillating discussion and critical reading of the manuscript. The research program in Dr Shukla's laboratory is supported by the Indian Institute of Technology Kanpur (IITK/BSBE/2014011), the Department of Science and Technology (DST), Council of Scientific and Industrial Research (CSIR) and the Wellcome Trust/DBT India Alliance. Dr Shukla is an Intermediate Fellow of Wellcome Trust/DBT India Alliance (IA/11/14/1/501285). Synthesis of BI-167107 in Dr Xin Chen's laboratory was supported by a grant from the National Science Foundation of China (No. 21272029). We thankfully acknowledge Dr Linton M. Traub, University of Pittsburgh, for providing Clathrin-TD plasmid. We thank Mr Arvind Kumar for excellent secretarial assistance. We thank Kumari Nidhi for help in the early stages of ERK assay and Dr Mithu Baidya in  $\beta_2$ AR endocytosis experiments. We also thank Prof. Ashwani K. Thakur for kindly allowing us to use the Fluorescence Spectrometer in his laboratory.

## Author contributions

P.K. designed and carried out the ELISA and coIP experiments for complex assembly and ERK binding and performed ERK assay for  $\beta_2$ AR; A.S. expressed and purified  $\beta$ arr1<sup>L68C</sup>, functionally validated its interaction with  $\beta_2$ V<sub>2</sub>R and carried out bimane fluorescence experiments with help from R.B.; R.B. cloned, expressed and purified  $\beta_2$ V<sub>2</sub>R (WT and  $\Delta$ ICL3) with help from P.K. and assisted in bimane fluorescence experiments; E.G. carried out the cross-linking coIP experiment to confirm the interaction of  $\beta_2$ AV<sub>2</sub>R <sup>$\Delta$ ICL3</sup> with  $\beta$ arr1 in cells and performed receptor internalization assays; X.C. provided BI-167107; P.G. carried out confocal microscopy with help from C.G. and ERK assay on  $\beta_2$ V<sub>2</sub>R constructs with help from P.K.; R.R. expressed and purified Fab30 with help from D.J., ScFv30 and Nb6B9; B.G. expressed and purified ERK2 and MEK1, and performed ERK2 phosphorylation. A.K.S. managed and supervised overall project. All authors contributed to data analysis, interpretation and writing of the manuscript.

**Additional information**

**Supplementary Information** accompanies this paper at <http://www.nature.com/naturecommunications>

**Competing financial interests:** The authors declare no competing financial interests.

**Reprints and permission** information is available online at <http://npg.nature.com/reprintsandpermissions/>

**How to cite this article:** Kumari, P. *et al.* Functional competence of a partially engaged GPCR- $\beta$ -arrestin complex. *Nat. Commun.* **7**, 13416 doi: 10.1038/ncomms13416 (2016).

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2016